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 Metastatic melanomas have extremely 
grave outcomes with median survival of 
around 6 months and a 5-year survival 
rate of 5 % ( 2,3 ). Th e most common can-
cers metastasizing to the adrenal glands 
are cancers of the lung and the gastroin-
testinal tract ( 8 ). In a study of nearly 6,000 
malignant melanoma patients, metastases 
to the adrenal glands were seen in 13 % of 
patients and were associated with mortal-
ity rates of over 75 % ( 2 ). 
 EUS-FNA is a novel method for diagnos-
ing adrenal lesions. When it is compared 
with the traditional diagnostic modalities, it 
is not only more accurate than imaging stud-
ies such as computated tomography, posi-
tron emission tomography, and magnetic 
resonance imaging, but it is also a very safe 
procedure with fewer complications than 
transcutaneous biopsies ( 5,6 ). EUS-FNA of 
the left  adrenal gland is a relatively simple 
procedure and can be performed by passing 
either a 22- or 25-gauge needle through the 
gastric wall using a curvilinear echoendo-
scope ( 4 ). On the other hand, EUS-FNA of 
the right adrenal gland is more challenging 
because the echoendoscope must be maneu-
vered carefully from within the second por-
tion of the duodenum in order to visualize 
the gland between the liver and the inferior 
vena cava ( 5 ). When compared with the 22-
gauge needle, 25-gauge needles are relatively 
more fl exible and are preferred for perform-
ing trans-duodenal FNAs. Although one 
report of successful utilization of EUS-FNA 
to diagnose bilateral adrenal histoplasmosis 
exists in the literature ( 9 ), this case high-
lights the use of EUS-FNA for the diagnosis 
of bilateral metastatic melanoma of the adre-
nal glands. 
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 To the Editor: Th e risk of malignancy 
in Crohn ’ s disease (CD) has been well 
described. Moreover, immunomodulators, 
such as azathioprine (AZA) and 6-mer-
captopurine (6-MP), and biological agents, 
such as infl iximab and adalimumab, may 
promote carcinogenesis ( 1 – 3 ). Splenic litto-
ral cell tumors are recently described tumors 
of vascular origin composed of endothelial 
cells, with typical microscopic and immuno-
histochemical features of splenic sinus lining 
cells ( 4 ). Clinical fi ndings are not specifi c, 
and outcome is unpredictable but usually 
benign, although a few cases with a malig-
nant behavior have been reported ( 5,6 ). 
 We report a 58-year-old Caucasian man 
with a long history of ileocolonic CD. He 
had required multiple resections. He had 
been steroid dependent since 2002 and 
had received repeated antibiotics because 
of perianal abscesses. In June 2003, he 
received infl iximab (5  mg / kg) induction 
therapy, discontinued later on because of 
an infusion reaction. He was put on AZA 
(2  mg / kg / day), which was stopped owing 
to severe bone marrow toxicity, and was 
then put on 6-MP, which was withdrawn 
owing to liver and pancreatic enzyme 
alterations. In 2004, he had a severe relapse 
of perianal disease, which required multi-
ple surgical drainages and local injections 
of infl iximab. In September 2009, he started 
adalimumab, which was again interrupted 
because of development of pancytopenia. 
Ten months later, the patient was admit-
ted to our hospital because of diarrhea, 
abdominal pain, fever (40 ° C), fatigue, and 
active drainage of perianal fi stulas. Physi-
cal examination revealed a splenomegaly, 
but no peripheral palpable lymph nodes. 
Blood tests showed pancytopenia with 
severe anemia (hemoglobin level 7.8  g / dl), 
lymphocytopenia (white blood cell count 
3,900 / μ l, lymphocytes 10 % ), and throm-
bocytopenia (platelets 67,000 / μ l). Evalu-
ation for infectious agents was negative. 
Abdominal ultrasound and computerized 
tomography (CT) scan showed splenom-
egaly (22  cm long on its major axis) with 
multiple hypodense lesions; liver was 
normal. Previous abdominal imaging, 
available since 2002, did not show any orga-
nomegaly. During hospitalization, leuko-
cytes went down to 770 / μ l. Bone marrow 
biopsy revealed a T-lymphocyte infi ltra-
tion (CD3  +  ; CD2  +  ; CD4  >  CD8) not 
diagnostic for lymphoproliferative disease; 
splenectomy was performed. Th e spleen 
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weighed 1,150  g. Macroscopically, the organ 
looked well capsulated, lacking signifi cant 
alteration. On histology, spleen paren-
chyma showed a slit-like anastomosing 
vascular proliferation with solid areas, 
with high proliferation index (Ki-67  + 
cells 25 % ) and spotty necrosis. On immu-
nohistochemistry, the cell lining the vascu-
lar spaces showed coexpression of factor 
VIII and other endothelial line markers, 
as well as histiocytic line markers such as 
KP1. Th is phenotype was consistent with 
littoral cell diff erentiation ( Figures 1 – 2 ). 
Th e fi nal diagnosis was littoral cell heman-
gioendothelioma (HE). Laparotomic liver 
biopsy evidenced a normal liver architec-
ture. Postoperative course was unevent-
ful. Blood cell count went back to normal. 
Littoral cell HE is frequently associated 
with cancers in other visceral organs or 
malignant lymphoma, but total body CT 
scan, technetium bone scintigraphy, and 
positron emission tomography excluded 
neoplastic infi ltration of other organs. 
 In conclusion, our patient with a long-
standing CD had a littoral splenic HE 
presenting with splenomegaly and hyper-
splenism. Th is presentation is not unusual: 
most cases of this tumor are asympto-
matic (  >  55 % ) and are only discovered 
incidentally, but clinically splenomegaly 
is almost always present; abdominal pain, 
pyrexia of unknown origin, symptoms of 
hypersplenism (thrombocytopenia and 
anemia), and portal hypertension may 
occasionally be seen. He had received 
both immunomodulators and anti-tumor 
necrosis factor (TNF) agents and had 
experienced recurrent perianal abscesses, 
suggesting a possible promoting role of 
chronic infection and immunosuppres-
sion in the pathogenesis of this rare tumor, 
as suggested by other authors. Bi  et al. 
( 7 ) have noted that 17 % of the cases of 
littoral splenic HE were associated with 
immunological or congenital disorders, 
such as CD, Wiskott – Aldrich syndrome, 
Epstein syndrome, lymphocytic colitis, 
ankylosing spondylitis, Gaucher ’ s dis-
ease, myelodysplastic syndrome, chronic 
glomerulonephritis, or aplastic anemia. To 
our knowledge, only one case of littoral HE 
in CD has been previously reported ( 8 ). 
Our patient is the fi rst one to be exposed 
to the new anti-TNF agents. Cancer risk 
 Figure 1 .  The splenic parenchyma is almost entirely replaced by a vascular proliferation of branching 
slit-like small blood vessels with solid areas and focal spotty necrosis. The proliferation surrounds the 
residual lymphoid structure (EE, overall magnifi cation  × 40). 
 Figure 2 .  The vascular proliferation shows marked and diffuse expression of endothelial markers 
(immunohistochemical staining for CD34; overall magnifi cation  × 100) and histiocytic cell line markers 
(immunohistochemical staining for Kp1; overall magnifi cation  × 100). 
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in patients treated with TNF- α antagonists 
is considered low, and a meta-analysis of 
randomized trials has found no diff erence 
between CD patients treated with biologics 
and controls ( 9 ). Recently, the rare hepat-
osplenic T-cell lymphoma ( 3 ) has been 
described in young subjects, and another 
meta-analysis has confi rmed an increased 
risk of lymphoma related to anti-TNF 
therapy ( 10 ). Lymphoma was our fi rst 
diagnostic hypothesis before splenectomy. 
Physicians caring for patients treated with 
biologics should be aware of the possibility 
of rarer tumors in the diff erential diagnosis 
of splenic focal lesions. On the basis of this 
case and previous reports on the occur-
rence of lymphoproliferative disorders and 
severe infections (tuberculosis) ( 11 ), we 
recommend regular follow-up abdominal 
ultrasound in the long-term monitoring of 
safety of anti-TNF agents. 
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 To the Editor: Now, molecular designed 
drugs can completely eliminate hepatitis C 
virus (HCV) without the use of interferon 
( 1,2 ). Coincidently, some drugs that are 
used to treat other diseases have been found 
to suppress HCV replication ( 3,4 ). A recent 
study reported that sorafenib, a standard 
drug for the management of advanced 
hepatocellular carcinoma, inhibits HCV 
replication by suppressing c-Raf ( 5 ). 
 We describe a patient in whom HCV 
disappeared during chemotherapy with 
trastuzumab, a monoclonal antibody that 
binds to human epidermal growth factor 
receptor 2 (HER-2, also known as ErbB-2, 
or c-neu) and is used to treat breast cancer 
( 6 ). Inhibition of HER-2 might be associ-
ated with HCV replication. 
 A 67-year-old woman with chronic 
hepatitis C genotype 2a infection started to 
receive chemotherapy for advanced breast 
cancer on 30 July 2009. Screening tests 
showed that she was anti-HCV positive. A 
tumor in left  mammary gland and the left  
axillary lymph nodes were palpable. Com-
puted tomography showed upper media-
stinal lymphadenopathy. Stage IV breast 
cancer (T1N2M1) was diagnosed. Histo-
logical examination showed that breast 
cancer cells were positive for estrogen 
receptor and HER-2, but negative for pro-
gesterone receptor. At the start of chemo-
therapy with 1  mg of anastrozole per day, 
she was well, with a height of 155  cm and 
a body weight of 58  kg. Th e laboratory 
values were as follows: hemoglobin con-
centration 15.5  g / dl, white blood cell count 
5,400 / mm 3 , platelet count 204,000 / mm 3 , 
aspartate aminotransferase 56  IU / l, alanine 
aminotransferase 93  IU / l,  γ -glutamyltrans-
ferase 52  IU / l, bilirubin 0.8  mg / dl, albumin 
4.1  g / dl, and HCV RNA 3.8 Log copies / ml 
by the COBAS TaqMan HCV assay (Roche 
Diagnostics, Tokyo, Japan), with a lower 
limit of detection of 10  IU / ml. Serological 
test showed that both hepatitis B surface 
antigen and anti-HB core were negative. 
Ultrasonography showed liver deformity 
with mild splenomegaly and no space-
occupying lesions in the liver. Elasto graphy 
showed mild hepatic fi brosis. On 11 Janu-
ary 2010, tamoxifen citrate was substituted 
for anastrozole because of tumor progres-
sion. From the start of chemotherapy, 
the serum HCV RNA level gradually 
increased. On 21 March 2010, the regimen 
for chemotherapy was switched to a com-
bination of trastuzumab and S-1 (a com-
bined preparation of tegafur, gimeracil, 
and oteracil potassium). Aft er 3 months, 
HCV RNA was not detected on real-time 
PCR. On 22 September 2010, the treatment 
regimen was changed to a combination of 
trastuzumab and exemestane. HCV RNA 
remained undetectable for 9 months. Th e 
serum alanine aminotransferase level fell 
to   <  40  IU / l since the time that HCV RNA 
had become undetectable ( Figure 1 ). 
 In vitro analysis indicated that NS5A 
protein of HCV altered epidermal growth 
factor (EGF) receptor traffi  cking ( 7 ) 
and inhibited mitogen-activated protein 
kinase signal transduction by binding to 
EGF receptor  (8) . Th ese fi ndings suggested 
that EGF signaling might be biologically 
relevant to HCV infection. HER-2 is a 
transmembrane tyrosine kinase with 40 % 
